Corcept Therapeutics Incorporated (CORT NASDAQ) stock market data APIs
$40.4704
-1.36(-3.4%)
as of February 6, 2026
Try our APIs with
free plan!
Corcept Therapeutics Incorporated Financial Data Overview
Price chart is built with
Anychart
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Prev. Close
40.4704
Open
39.1113
High
40.4778
Low
38.3197
52 wk Range
32.9906-117.33
Market Cap
4 302 M
P/E Ratio
46.931
Shares Outstanding
105 M
Revenue
741 M
EPS
0.16
Beta
0.264
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Corcept Therapeutics Incorporated (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Corcept Therapeutics Incorporated data using free add-ons & libraries
Get Corcept Therapeutics Incorporated Fundamental Data
Corcept Therapeutics Incorporated Fundamental data includes:
- Net Revenue: 741 M
- EBITDA: 66 713 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corcept Therapeutics Incorporated News
New
February 2026's Top Growth Stocks With Strong Insider Ownership
As February 2026 begins, U.S. stock markets have shown strong momentum with major indices like the Dow and S&P 500 posting significant gains, despite recent economic uncertainties such as a partial go...
Insiders Favor These 3 High Growth Companies
As the U.S. stock market kicked off February with a strong performance, highlighted by significant gains in major indices like the Dow Jones and S&P 500, investors are keenly observing growth companie...
3 Growth Companies With High Insider Ownership And 21% Revenue Growth
As February 2026 begins, U.S. stock indexes have shown a strong start with the Dow climbing 515 points and the S&P 500 nearing record highs, reflecting a positive sentiment in the market despite ongoi...
Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then
Some Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders are probably rather concerned to see the share price fall 45% over the last three months. In contrast the stock is up over the last th...
Get Corcept Therapeutics Incorporated fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
